PatchSiren cyber security CVE debrief
CVE-2026-50034 Apollo Pharmacy CVE debrief
The CVE-2026-50034 vulnerability affects the Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT), allowing attackers within BLE communication range to passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values. This vulnerability has a HIGH severity with a CVSS Score of 7.1. Healthcare organizations and individuals using this system should be aware of the potential risks and take necessary precautions. The CVE record was published on 2026-06-19T00:16:47.980Z and has not been modified since then. Further investigation and verification are necessary to fully understand the scope of the vulnerability and its potential impact.
- Vendor
- Apollo Pharmacy
- Product
- Blood Glucose Monitoring System (Model No. APG-01 BT)
- CVSS
- HIGH 7.1
- CISA KEV
- Not listed in stored evidence
- Original CVE published
- 2026-06-19
- Original CVE updated
- 2026-06-22
- Advisory published
- 2026-06-19
- Advisory updated
- 2026-06-22
Who should care
Healthcare organizations and individuals using Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT) should be aware of this vulnerability, as it allows attackers to intercept sensitive health-related information, including glucose measurement values. The vulnerability poses a significant risk to patient data and healthcare services, making it essential for healthcare organizations to take necessary precautions.
Technical summary
CVE-2026-50034 is a HIGH-severity vulnerability (CVSS Score: 7.1) affecting Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT). An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values. The vulnerability is related to the BLE communication protocol, which allows for the interception of sensitive information. The affected system is widely used in healthcare settings, making it a high-priority target for attackers.
Defensive priority
High-priority defensive actions are recommended to mitigate the risk of sensitive health-related information interception. Defenders should focus on implementing compensating controls, monitoring for suspicious activity, and applying vendor remediation or patches when available.
Recommended defensive actions
- Implement compensating controls to limit BLE communication range
- Monitor for suspicious activity and implement exception tracking
- Inventory and verify the affected system's presence in the environment
- Apply vendor remediation or patches when available
- Consider disabling BLE or restricting its use in sensitive environments
- Review and update incident response plans to address potential breaches
- Conduct regular security audits and risk assessments to identify vulnerabilities
Evidence notes
The CVE record and NVD entry provide limited information about the vulnerability. Further investigation and verification are necessary to fully understand the scope of the vulnerability and its potential impact. The affected system is widely used in healthcare settings, making it a high-priority target for attackers. Defenders should verify the presence of the affected system in their environment and review compensating controls for exposed systems while remediation is scheduled and verified.
Official resources
AI-assisted PatchSiren debrief based on the supplied source corpus. The CVE record was published on 2026-06-19T00:16:47.980Z and has not been modified since then.